YCBD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.794

Open

0.754

VWAP

1.00

Vol

407.00K

Mkt Cap

8.00M

Low

0.730

Amount

311.00K

EV/EBITDA(TTM)

--

Total Shares

11.00M

EV

6.00M

EV/OCF(TTM)

--

P/S(TTM)

0.00

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Show More

Events Timeline

(ET)

2025-12-19

15:30:00

cbdMD Enters Securities Purchase Agreements Issuing 1M Convertible Preferred Shares

2025-12-19

15:30:00

cbdMD Trading Resumes

2025-12-19

14:10:00

cbdMD Trading Halted, News Pending

2025-11-21 (ET)

2025-11-21

08:32:38

cbdMD projects FY25 revenue between $19.1M and $19.3M, down from $19.5M last year

2025-10-09 (ET)

2025-10-09

10:05:50

cbdMD's Herbal Oasis Forms Distribution Alliance with Bevtalk

2025-04-22 (ET)

2025-04-22

10:19:29

cbdMD announces automatic conversion of shares, 1-for-8 reverse stock split

2025-01-03 (ET)

2025-01-03

16:12:52

cbdMD discloses NYSE listing compliance notice

News

an image of Newsfilter

01-29Newsfilter

PinnedcbdMD Integrates Bluebird Assets to Enhance Compliance

an image of Newsfilter

01-14Newsfilter

cbdMD Acquires Bluebird Botanicals, Strengthening Long-Term Growth Foundation

an image of seekingalpha

01-14seekingalpha

cbdMD Acquires Bluebird Botanicals Assets, Strengthening Revenue Base

an image of Benzinga

2025-12-22Benzinga

Trump Media Completes $6 Billion Merger with TAE Technologies, Stock Rises

an image of Benzinga

2025-12-22Benzinga

Greenlane Holdings Inc. CEO Resigns, Shares Drop 11%

an image of Yahoo Finance

2025-12-20Yahoo Finance

cbdMD Inc (YCBD) Q4 2025 Earnings Call Summary: Focus on Strategic Growth Despite Regulatory Hurdles

1 Analyst Rating

Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Maxim

Buy

downgrade

$3 -> $2

AI Analysis

2025-08-20

Reason

Maxim

Price Target

$3 -> $2

AI Analysis

2025-08-20

downgrade

Buy

Reason

Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.

Maxim

Buy

downgrade

$16 -> $3

2025-05-22

Reason

Maxim

Price Target

$16 -> $3

2025-05-22

downgrade

Buy

Reason

Valuation Metrics

The current forward P/E ratio for cbdMD Inc (YCBD.A) is -5.27, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess cbdMD Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-5.00

Current PE

-5.27

Overvalued PE

6.62

Undervalued PE

-16.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-53.84

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

129.00

Undervalued EV/EBITDA

-236.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

0.88

Current PS

0.56

Overvalued PS

2.01

Undervalued PS

-0.25

Financials

AI Analysis

Annual

Quarterly

Whales Holding YCBD

Trading Trends

People Also Watch

Frequently Asked Questions

What is cbdMD Inc (YCBD) stock price today?

The current price of YCBD is 0.771 USD — it has increased 2.25 % in the last trading day.

What is cbdMD Inc (YCBD)'s business?

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

What is the price predicton of YCBD Stock?

Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is cbdMD Inc (YCBD)'s revenue for the last quarter?

cbdMD Inc revenue for the last quarter amounts to 5.00M USD, increased 3.61 % YoY.

What is cbdMD Inc (YCBD)'s earnings per share (EPS) for the last quarter?

cbdMD Inc. EPS for the last quarter amounts to -0.08 USD, decreased -94.33 % YoY.

How many employees does cbdMD Inc (YCBD). have?

cbdMD Inc (YCBD) has 42 emplpoyees as of January 30 2026.

What is cbdMD Inc (YCBD) market cap?

Today YCBD has the market capitalization of 8.00M USD.